TransMedics Group (TMDX) Misses Q2 EPS by 6c, Revenues Beat; Raises FY Revenue Guidance

TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of ($0.41), $0.06 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $16.2 million.

GUIDANCE:

TransMedics Group raises FY2022 revenue to $67-75 million, versus the consensus of $66.97 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight